Oxford Immunotec aims to price $50 million public sale of common stock

J.P. Morgan, Piper Jaffray, Cowen, Baird help fund sales and marketing

By Devika Patel

Knoxville, Tenn., Jan. 28 – Oxford Immunotec Global plc will price a $50 million public offering of common stock with a 30-day, $7.5 million greenshoe option, according to a preliminary prospectus supplement filed Wednesday with the Securities and Exchange Commission.

J.P. Morgan and Piper Jaffray are the bookrunning managers. Cowen and Co. and Baird are the co-managers.

Proceeds will be used to hire additional sales and marketing personnel, to accelerate commercial activities, for research and development and for working capital and general corporate purposes, including potential acquisitions.

The diagnostics company is based in Abingdon, England.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.